Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transformed follicular lymphoma (tFL): consolidation therapy may improve survival

Transformed follicular lymphoma (tFL): consolidation therapy may improve survival Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identified from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Irish Journal of Medical Science (1971 -) Springer Journals

Transformed follicular lymphoma (tFL): consolidation therapy may improve survival

Loading next page...
1
 
/lp/springer_journal/transformed-follicular-lymphoma-tfl-consolidation-therapy-may-improve-AtbZyRA45U

References (20)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Royal Academy of Medicine in Ireland
Subject
Medicine & Public Health; Internal Medicine; General Practice / Family Medicine
ISSN
0021-1265
eISSN
1863-4362
DOI
10.1007/s11845-017-1594-z
pmid
28321641
Publisher site
See Article on Publisher Site

Abstract

Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identified from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had

Journal

Irish Journal of Medical Science (1971 -)Springer Journals

Published: Mar 21, 2017

There are no references for this article.